Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options-A Single-Center Experience.
Strassl I, Nikoloudis A, Machherndl-Spandl S, Buxhofer-Ausch V, Binder M, Wipplinger D, Stiefel O, Kaynak E, Milanov R, Aichinger C, Nocker S, Bauer T, Kreissl S, Girschikofsky M, Petzer A, Weltermann A, Clausen J. Strassl I, et al. Among authors: petzer a. Cancers (Basel). 2023 Dec 7;15(24):5738. doi: 10.3390/cancers15245738. Cancers (Basel). 2023. PMID: 38136284 Free PMC article.
Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletion.
Nikoloudis A, Buxhofer-Ausch V, Aichinger C, Binder M, Hasengruber P, Kaynak E, Wipplinger D, Milanov R, Strassl I, Stiefel O, Machherndl-Spandl S, Petzer A, Weltermann A, Clausen J. Nikoloudis A, et al. Among authors: petzer a. Cytotherapy. 2024 May;26(5):490-497. doi: 10.1016/j.jcyt.2024.02.003. Epub 2024 Feb 15. Cytotherapy. 2024. PMID: 38385908 Free article.
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Ludwig H, Melchardt T, Sormann S, Schreder M, Andel J, Hartmann B, Tinchon C, Zojer N, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bozic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Zabernigg A, Knop S, Paiva B, Greil R. Ludwig H, et al. Among authors: petzer a. Am J Hematol. 2024 May;99(5):1008-1011. doi: 10.1002/ajh.27280. Epub 2024 Feb 29. Am J Hematol. 2024. PMID: 38425185 Clinical Trial.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group. Lang I, et al. Lancet Oncol. 2013 Feb;14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10. Lancet Oncol. 2013. PMID: 23312888 Clinical Trial.
Overview of popular cosmeceuticals in dermatology.
Crous C, Pretorius J, Petzer A. Crous C, et al. Among authors: petzer a. Skin Health Dis. 2024 Feb 7;4(2):e340. doi: 10.1002/ski2.340. eCollection 2024 Apr. Skin Health Dis. 2024. PMID: 38577050 Free PMC article. Review.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Dreyling M, Fowler NH, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, María Ferreri AJ, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Paule I, Zia A, Awasthi R, Han X, Germano D, O'Donovan D, Ramos R, Maier HJ, Masood A, Thieblemont C, Schuster SJ. Dreyling M, et al. Among authors: petzer al. Blood. 2024 Apr 25;143(17):1713-1725. doi: 10.1182/blood.2023021567. Blood. 2024. PMID: 38194692 Free PMC article. Clinical Trial.
A Multitarget Approach against Neuroinflammation: Alkyl Substituted Coumarins as Inhibitors of Enzymes Involved in Neurodegeneration.
Berrino E, Carradori S, Carta F, Melfi F, Gallorini M, Poli G, Tuccinardi T, Fernández-Bolaños JG, López Ó, Petzer JP, Petzer A, Guglielmi P, Secci D, Supuran CT. Berrino E, et al. Among authors: petzer a. Antioxidants (Basel). 2023 Nov 25;12(12):2044. doi: 10.3390/antiox12122044. Antioxidants (Basel). 2023. PMID: 38136164 Free PMC article.
Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer.
Doleschal B, Taghizadeh H, Lentner T, Riedl JM, Granitzer J, Morariu D, Decker J, Aichberger KJ, Webersinke G, Kirchweger P, Petzer A, Rumpold H. Doleschal B, et al. Among authors: petzer a. ESMO Open. 2023 Dec;8(6):102064. doi: 10.1016/j.esmoop.2023.102064. Epub 2023 Nov 16. ESMO Open. 2023. PMID: 37977001 Free PMC article.
Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients-A Retrospective Single-Center Analysis.
Nikoloudis A, Neumann IJ, Buxhofer-Ausch V, Machherndl-Spandl S, Binder M, Kaynak E, Milanov R, Nocker S, Stiefel O, Strassl I, Wipplinger D, Moyses M, Kerschner H, Apfalter P, Girschikofsky M, Petzer A, Weltermann A, Clausen J. Nikoloudis A, et al. Among authors: petzer a. Vaccines (Basel). 2023 Sep 28;11(10):1534. doi: 10.3390/vaccines11101534. Vaccines (Basel). 2023. PMID: 37896938 Free PMC article.
249 results